A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia

NCT05734807 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic HBV Infection

Interventions

DRUG: Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs)
DRUG: HH-003 and NrtIs
DRUG: HH-003, NrtIs and PEG-IFN-α

Sponsor

Huahui Health